We come together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease.
On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop and deliver life-changing therapies.
We continuously seek to understand the diverse perspectives of rare patients to courageously forge new paths that can make a difference in their lives and provide hope for today and tomorrow.
We are committed to broad access for our FDA-approved therapies, and we provide personalized clinical support services through the Total Care Hub.
We are dedicated to staying informed and engaged on topics that may impact the rare disease community, featuring community members and sharing what we learn. Find info at our Pathfinder.
On February 23, 2021, the Black Women’s Health Imperative (BWHI) held the first public meeting of the Rare Disease Diversity Coalition (RDDC) with more than 200 rare disease community members joining together to endorse an ambitious platform of 10 initiatives to achieve tangible solutions to address issues, including delays in diagnosis and treatment for diverse patients. We’re proud to work closely with the leaders of the BWHI to spearhead the formation of the RDDC.
On February 23, 2021, the nonprofit organization RARE-X announced plans to expand its work helping patient groups collect structured, standardized research-ready data that will better support the development of future treatments. This foundational work is made possible through a funding commitment from Travere Therapeutics.
Valarie describes her family’s journey with baby Delila who has Alagille syndrome.
SAN DIEGO, Feb. 18, 2021 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the European Commission (EC) has granted orphan designation to sparsentan for the treatment of IgA nephropathy (IgAN), a rare kidney disorder and a leading cause of end-stage kidney disease (ESKD).
Telehealth-first care. That’s the approach that many clinics and health centers adopted for preventative and follow up visits in the wake of the pandemic’s arrival. Online and on-phone visits enable healthcare professionals and their patients to manage conditions without the burden of travel or undo risk of exposure to the coronavirus.
Retrophin is now Travere Therapeutics.
© 2021 Travere Therapeutics, Inc. All rights reserved. For US audiences. Chenodal®, Cholbam® and Total Care HUB® are registered trademarks of Travere Therapeutics, Inc. Thiola® and Thiola EC® are registered trademarks of Mission Pharmacal Company.
Travere Therapeutics Recognizes Rare Disease Day 2021 and the Importance of Working Together to Innovate and Address Healthcare Disparities in Rare Disease
NewsSAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) will join the National Organization for Rare Disorders (NORD), the European Organisation for Rare Diseases (EURORDIS), EveryLife Foundation for Rare Diseases, Global Genes, and rare disease advocates and patients worldwide in recognizing February 28 as Rare Disease Day 2021.
Read the full press release >